Is a British-Swedish innovative biopharmaceutical company, which focuses on research, development and commercial use of prescription drugs.
Annual investments of the company into R&D exceed USD 4 billion. The company leads in such therapeutic spheres as cardiology, pulmonology, oncology, neurology and psychiatry, gastroenterology, virology, etc.
The company holds its place in top-12 of pharmaceutical manufacturers of Russia and in top-10 of the most influential members of the pharmaceutical market.
The construction began in April of 2011. Now, the erection of the production premises is over, the installation of the equipment is going on.